Abstract Number: PB1479
Meeting: ISTH 2020 Congress
Theme: Platelet Disorders and von Willebrand Disease » Platelet Function Disorders, Acquired
Background: Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by isolated thrombocytopenia in the absence of other causes or disorders. Bleeding and fatigue are the most common manifestation. The medications used to treat ITP include: corticosteroids, intravenous immunoglobulin, immunosuppressants, splenectomy and thrombopoietin receptor agonists.
Aims: Presenting the main challenges related to the treatment of ITP as resulting from our own experience and to show the impact on the quality of life
Methods: We present two cases of ITP that required different treatments for the control of haemorrhagic phenomena and to show the impact on the quality of life of patients. The quality of life was related to the number of bleeding episodes, the length of hospitalization and the side effects of the treatments performed.
Results:
Case 1: A 20 years old woman diagnosed with ITP at 13 years old. She received corticosteroids that did not lead to a sustained response and after six months, the splenectomy was performed. The disease relapsed with the severe menorrhagia, severe anemia (Hb- 1.9g/dl). Corticosteroids/immunosuppressants were administrated with severe side effects (Cushing syndrome, depression, infections). When she was 19 years old, romiplostim was started. Initially it was difficult to maintain the platelets above 50.000/mmc but she had not bleeding episode, no hospitalization.
Case 2: A 74 years old woman and when she was 62 years old was diagnosed with ITP. She received corticosteroids and then the splenectomy was performed. The disease relapsed with the severe purpura and corticosteroids were administrated with severe side effects (diabetes mellitus, arterial hypertension). When she was 72 years old eltrombopag was started with a good response at doses of 25 mg/day and no bleeding episode.
Conclusions: The main goal of treatment today should be to improve the quality of life of patients with ITP, the thrombopoietin receptor agonists being a solution in this regard.
To cite this abstract in AMA style:
Tarniceriu CC, Ștefan Rudeanu A, Delianu C, Gradinaru I, Hurjui LL. Quality of Life Today in Patients with Chronic Immune Thrombocytopenic Purpura [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/quality-of-life-today-in-patients-with-chronic-immune-thrombocytopenic-purpura/. Accessed October 1, 2023.« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/quality-of-life-today-in-patients-with-chronic-immune-thrombocytopenic-purpura/